Effect of LRRK2 Mutations on PD-associated Inflammation
Access to Data and Biospecimens, 2014
Increased inflammation is associated with the progression and possibly even onset of Parkinsonís disease (PD). Mutations in the LRRK2 gene are also associated with PD, and recent evidence points to a role for LRRK2 to modulate inflammatory pathways. This project aims to investigate inflammatory cytokines (small proteins involved in cell signaling) in people with LRRK2 mutations who have and who do not have PD. Outcomes will provide more information on the role of inflammation in PD.†
Serum and cerebrospinal fluid samples will be obtained from the LRRK2 Cohort Consortium through The Michael J. Fox Foundation. Inflammatory cytokines will be measured by ELISA (a test that uses antibodies and color change to identify a substance). Statistical analysis will be used to see how changes in inflammatory cytokines relate to clinical measures of PD in LRRK2 mutation carriers with and without PD.
Relevance to Diagnosis/Treatment of Parkinsonís Disease:†
The results of this study could provide more information regarding the utility of anti-inflammatory drugs for the treatment of Parkinsonís disease. Results will also provide information about how LRRK2 mutations influence the inflammatory response in PD.†
We anticipate that increased inflammatory cytokines will be associated with a number of clinical signs or measures of PD. If increased inflammation is associated with early signs/symptoms of PD, then this will provide more evidence of a role for inflammation in PD progression. The identification of early markers of PD is crucial for efficient therapeutic intervention.
Senior Research Fellow at The University of Sydney
Location: Sydney, NSW, Australia
Professor of Neuroscience and NHMRC Senior Principal Research Fellow at University of New South Wales and Neuroscience Research Australia
Location: Sydney, Australia